

Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity

Mitsuo Sekimoto,^a Yasunao Hattori,^b Keiji Morimura,^c Mitsuru Hirota,^d and Hidefumi Makabe^{a*}

^a*Sciences of Functional Foods, Graduate School of Agriculture, Shinshu University, 8304, Minami-minowa, Kami-ina, Nagano 399-4598, Japan*

^b*Department of Chemistry, Graduate School of Medicinal Science, Kyoto Prefectural University of Medicine, Kita-ku, Kyoto 603-8334, Japan*

^c*Geol Cosmetics. Co., LTD, 111-1, Shinmura, Katsuragi, Nara 639-2121, Japan*

^d*Department of Bioscience and Biotechnology, Faculty of Agriculture, Shinshu University, 8304, Minami-minowa, Kami-ina, Nagano 399-4598, Japan*

*Corresponding author. Tel. +81 265 77 1630; fax +81 265 77 1700, e-mail: makabeh@shinshu-u.ac.jp


Abstract: Stereoselective syntheses of daedalin A and quercinol, an enantiomer of daedalin A, is described. The tyrosinase inhibitory activities of daedalin A and quercinol were examined. The activity of quercinol was weaker than that of daedalin A at high concentration.

Dermal hyper-pigmentation, caused by the accumulation of melanin, is initiated by oxidation of tyrosine by tyrosinase, a key enzyme of melanin biosynthesis.¹ Tyrosinase inhibitors such as arbutin, kojic acid, ellagic acid, and rucinol have been used as pharmaceutical constituents of cosmetics in order to prevent hyper-pigmentation. In an effort to find new types of tyrosinase inhibitors, we have screened culture broths from mushroom mycelia for tyrosinase inhibitory activity, and found that the mycelial culture of *Daedalia dickinsii* showed significant activity. Based on the spectroscopic data, the bioactive compound was elucidated as (2*R*)-6-hydroxymethyl-2-methyl-2*H*-chromene, named daedalin A (**1**).^{2,3} We have synthesized racemic **1** and it showed weaker activity than **1**.³ Quercinol (**2**), an enantiomer of daedalin A (**1**), was also isolated from the fungus of *Daedalea quercina* by Hertweck and co-workers.⁴ They reported that compound **2** showed anti-inflammatory activity.⁴ It is very difficult to obtain enough amount of daedalin A (**1**) and quercinol (**2**) for the biological study because the mycelia cultures of *Daedalia dickinsii* and/or *Daedalea quercina* are limited. Thus, syntheses of **1**, **2**, and their analogues are important for the biological study. Especially, synthesis of **2** is required because the tyrosinase inhibitory activity of **2** has not been reported yet. Herein, we wish to describe an asymmetric synthesis of **1** and **2** and their tyrosinase inhibitory activity (Figure 1).



Figure 1. The structure of daedalin A (1) and quercinol (2).


The synthesis of daedalin A (1) is described as follows. Compound **4** was synthesized from 4-methoxyphenol and vinyloxirane using Pd-catalyzed *O*-alkylation using Kirschleger's method with modification.⁵ In this reaction Kirschleger used 1.5 mol% of Pd(PPh₃)₄ at room temperature, however, sometimes the yield of desired product was low. Thus, we used 1 mol% of Pd(PPh₃)₄ at 0°C to give desired product in high yield. Acetylation, Claisen rearrangement followed by Sharpless asymmetric epoxidation gave **9**.^{5,6} Reduction with LiAlH₄ followed by protecting 1,2-diol with 2,2-dimethoxypropane afforded **11**. Oxidative demethylation of **11** with ceric ammonium nitrate (CAN) afforded **12** only in 21% yield with complex mixture.⁷ Probably the product was decomposed under acidic medium. Thus, we used silver (II) dipicolinate {Ag(DPAH)₂} in the presence of AcONa as an oxidant to give **12** in 96% yield.⁸ This method is useful for oxidizing acid sensitive substrate because oxidation can be proceeded under neutral medium. Transformation from **12** to **14** was achieved using Kirschleger's method.⁶ Protection of the hydroxy groups of **14** with TBSCl and imidazole afforded **15**. Treatment of **15** with DDQ afforded **16**.⁹ Finally, deprotection of the TBS ether of **16** with TBAF furnished daedalin A (1) in good yield. Recrystallization (CHCl₃) gave colourless solid whose melting point was 136-138 °C. The specific rotation value of synthetic **1** was much higher than that of reported. All the spectral data of synthetic **1** were in good agreement with those of natural **1**. (Scheme 1).²



Scheme 1. Synthesis of daedalin A (**1**).

Reagents and conditions: (a) 0.5 mol % of Pd(PPh₃)₄, CH₂Cl₂, 0°C (93%); (b) Ac₂O, Et₃N, DMAP, AcOEt (quant.). (c) HCl (gas), CH₂Cl₂ (99%). (d) MOMCl, *i*-Pr₂NEt, CH₂Cl₂ (99%). (e) K₂CO₃, MeOH (quant.). (f) TBHP, Ti(O-*i*Pr)₄, L-(+)-DET, CH₂Cl₂ (78%). (g) LiAlH₄, diethyl ether, (88%). (h) DMP, *p*-TsOH (quant.). (i) Ag(DPAH)₂, AcONa, MeCN-H₂O (96%). (j) 1N HCl, MeOH (90%). (k) Red-Al, THF, -78 °C (92%). (l) TBSCl, imidazole, DMF (quant.). (m) DDQ, benzene (81%). (n) TBAF, THF (95%).

Synthesis of quercinol (**2**) was achieved as the same procedure of daedalin A (**1**) except that D-(−)-DET was used in the Sharpless epoxidation. The melting point and specific rotation values were higher than those reported. All the spectral data of synthetic **2** were in good agreement with those of natural **2** (Scheme 2).⁴



Scheme 2. Synthesis of quercinol (**2**).

Reagent and condition: (a) TBHP, Ti(O-*i*Pr)₄, D-(−)-DET, CH₂Cl₂ (89%).

The HPLC analysis of the synthetic **1** and **2** using chiral column showed more than 99% ee, respectively.

The tyrosinase inhibitory activities of **1** and **2** were examined. Interestingly, the tyrosinase inhibitory activity of **2** was weaker than that of **1** at higher concentration (400 μM). This result suggested that the mechanism of action of quercinol (**2**), which has an opposite stereochemistry at C-2 position, might be different from that of daedalin (**1**) in the tyrosinase inhibitory activity (Table 1).³

Table 1. Tyrosinase inhibitory activities of **1**, **2** and \pm daedalin A.

compound	Inhibition \pm SD (%) ^a			IC ₅₀ (μmol/l)
	100 μM	200 μM	400 μM	
daedalin A (1)	28.6 \pm 5.0	48.4 \pm 1.1	61.6 \pm 1.0	208
quercinol (2)	30.7 \pm 6.7	43.9 \pm 1.2	48.1 \pm 1.7	490
\pm daedalin A	23.7 \pm 5.7	45.5 \pm 3.1	55.6 \pm 1.1	289

^aEach value is expressed as the means \pm SD from three tests.

In summary asymmetric syntheses of daedalin A (**1**) and quercinol (**2**) was achieved. The tyrosinase inhibitory activity of **2** was weaker than that of **1** at high concentration. The study of the inhibitory mechanism of **2** is currently underway.

Supplementary data

Supplemental material available: spectroscopic and physical data of **1** and **2**, biological assays. Supplementary data associated with this article can be found, in the online version, at doi:

References and notes

1. Hearing, V. J.; Jiménez, M. *Int. J. Biochem.* **1987**, *19*, 1141-1147.
2. Morimura, K.; Yamazaki, C.; Hattori, Y.; Makabe, H.; Kamo, T.; Hirota, M. *Biosci. Biotechnol. Biochem.* **2007**, *71*, 2837-2840.
3. Morimura, K.; Hiramatsu, K.; Yamazaki, C.; Hattori, Y.; Makabe, H.; Hirota, M. *Biosci. Biotechnol. Biochem.* **2009**, *73*, 627-632.
4. Gebhart, P.; Dornberger, K.; Gollmick, F. A.; Gräfe, U.; Härtl, A.; Görls, H.; Schlegel, B.; Hertweck, C. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2558-2560.
5. Goujon, J. -Y.; Duval, A.; Kirschleger, B. *J. Chem. Soc. Perkin Trans. 1* **2002**, 496-499.
6. Bouzbouz, S.; Goujon, J. -Y.; Deplanne, J.; Kirschleger, B. *Eur. J. Org. Chem.* **2000**, 3223-3228.
7. Kirschleger and co-workers reported that **9** was obtained in 90% yield using CAN as an oxidant.⁶
8. Kloc, K.; Mlochowski, J.; Syper, L. *Chem. Lett.* **1980**, 725-728.
9. Trost, B. M.; Shen, H. C.; Surivet, J. -P. *Angew. Chem. Int. Ed.* **2003**, *42*, 3943-3947.